Hepatology is going through significant and extraordinary changes. The Conference Future Scenarios in Hepatology is included in this context
Nowadays, in more than 90% of cases, the C virus, one of the most common causes of chronic hepatic disease, up to cirrhosis and its complications, can be definitively eradicated and new drugs are coming to further optimize these results. It is an epochal fact: those who discovered this virus in 1989, today can assist in its elimination. This will have a strong and significant social impact, even if those cases of advanced cirrhotic disease existing before viral eradication was possible will remain, and will still require controls and treatments
Another area that is experiencing profound changes is that of hepatic steatosis, often referred to as NAFLD, English acronym for Non-Alcoholic Fatty Liver Disease. The international scientific community believes that in about 15 years this metabolic hepatic disease will be the most common among liver diseases. This condition, even met in childhood, has increasingly highlighted its potential to evolve to cirrhosis and all its complications. This fact has an inevitable relapse at a social level since it is correlated to daily habits and lifestyles.
At the end of the second day of the conference, a reading on "Latest News in Treatment of PBC" will be held.
The conference will be the occasion to deepen these issues regarding the aspects of prevention, early diagnosis and therapeutic possibilities.
Two sessions:
NEW PARADIGMS IN CHRONIC HEPATITIS HCV IN THE ERA OF DAA:
The Effectiveness of Therapy: M. Brunetto
The Management of Non responders and Special Populations: A. Aghemo
Treatment with DAA and Hepatic Fibrosis, is regression possible after SVR?: M. Pinzani
Treatment with DAA and Non invasive Evaluation of Hepatic Fibrosis: L. Casterà
Treatment with DAA and Histological Evalutation of Hepatic Fibrosis: A. Baiocchini
Treatment with DAA and Portal Hypertension, is reduction possible after SVR?: J.C. Garcia Pagan
Treatment with DAA and HCC: L. Bolondi
NAFLD-NASH: AN EVOLUTIVE PATHOLOGY:
NAFLD Epidemiology: E. Bugianesi
Steatosis in Pediatrics, a New Social Emergency: V. Nobili
NAFLD and Metabolic Disease: R. Calafiore
Inflammation and Fibrosis in NAFLD: Marra
Microbiota and NAFLD: A. Gasbarrini
NAFLD Susceptibility Testing, Applications in Practical Medicine: E. Giardina
NAFLD, Non invasive Diagnosis: S. Petta
NAFLD, Histological Diagnosis: G. Faa
NAFLD and HCC: A. Mazzocca
Therapeutic Approaches in NAFLD: M. Marzioni
READING:
Prospects for Management and Treatment of CBP Patients: D. Alvaro
